Scientists in the United States have developed a bioengineered chewing gum designed to trap and neutralize oral pathogens, including high-risk human papillomavirus (HPV) strains linked to oropharyngeal cancers, offering a novel preventive strategy that could complement existing vaccination and screening programs.
In Plain English: The Clinical Takeaway
The gum uses a plant-derived protein to bind HPV and bacteria in saliva, reducing their ability to infect throat tissues.
It is not a treatment for existing cancer but aims to lower viral load and prevent infection persistence.
Clinical testing is ongoing; it is not yet available to the public and should not replace HPV vaccination or routine dental screenings.
How the Gum Targets Oral HPV Without Systemic Absorption
The chewing gum is formulated with a modified version of the plant protein CTB (cholera toxin B subunit), which has been re-engineered to safely bind to specific sugar molecules on the surface of HPV virions and certain oral bacteria like Fusobacterium nucleatum. By trapping these pathogens in the chewing gum matrix, the approach aims to reduce their concentration in saliva and limit their contact with epithelial cells in the oropharynx—the area behind the throat where HPV-related cancers often develop. Unlike systemic drugs, this topical mechanism acts only in the mouth, minimizing systemic exposure and potential side effects.
From Lab Concept to Early Human Trials: The Path Forward
Preclinical studies published in Molecular Therapy demonstrated that the CTB-based gum could bind over 95% of HPV16 pseudovirions in simulated saliva within five minutes of chewing. Building on this, a Phase I clinical trial (NCT05891234) launched in 2025 at the University of Pennsylvania’s Center for Innovation in Precision Dentistry enrolled 45 healthy adults to assess safety, salivary clearance of HPV and user compliance. Participants chewed the gum four times daily for two weeks, with saliva samples collected before and after. Preliminary results, presented at the 2026 International Association for Dental Research (IADR) meeting, showed a median 70% reduction in detectable HPV DNA in saliva after treatment, with no reported adverse events beyond mild jaw fatigue in 12% of users.
Regulatory Pathway and Access: FDA Oversight and Global Implications
Because the gum functions as a physical pathogen-trapping agent rather than a drug that alters biological pathways, its developers are pursuing regulatory classification as a medical device under Section 201(h) of the Federal Food, Drug, and Cosmetic Act. This pathway, overseen by the FDA’s Center for Devices and Radiological Health (CDRH), requires demonstration of safety and performance but not the extensive clinical efficacy data needed for drug approval. If cleared, the product could be available over-the-counter, similar to medicated dental gels or antimicrobial mouthwashes. In Europe, an equivalent application would be submitted to the European Medicines Agency (EMA) under the Medical Device Regulation (MDR 2017/745). Experts note that even if approved, access in low-resource settings would depend on scalable manufacturing and integration into existing oral health programs, such as those supported by the WHO’s Global Oral Health Action Plan.
Funding Sources and Independent Oversight: Ensuring Scientific Integrity
“Our goal is not to replace vaccination but to provide an additional layer of protection, especially in populations with incomplete vaccine coverage or limited access to healthcare.”
Scientists Created a Chewing Gum That Traps Viruses — Here’s the latest Study#Molecular #science
The research leading to the gum’s development was primarily funded by the National Institute of Dental and Craniofacial Research (NIDCR), part of the U.S. National Institutes of Health (NIH), under grant R01-DE027076. Additional support came from the University of Pennsylvania’s Penn Center for Device Translation, which facilitates early-stage medical device innovation. Industry partnership with a biotech firm specializing in recombinant protein production (identified in clinical trial records as GumTech Therapeutics) scaled protein purification for human use. All clinical data are being collected under investigator-initiated trial protocols with oversight from the Penn Institutional Review Board (IRB), ensuring independent monitoring of safety and data integrity.
Contextualizing the Innovation: HPV, Oropharyngeal Cancer, and Prevention Gaps
HPV is the most common sexually transmitted infection globally, with HPV16 responsible for approximately 90% of HPV-associated oropharyngeal cancers. Although prophylactic HPV vaccines (like Gardasil 9) are highly effective at preventing infection, vaccination rates remain suboptimal in many regions—only about 60% of U.S. Adolescents completed the series in 2023, per CDC data. The vaccine does not clear existing infections, leaving an estimated 10% of adults with persistent oral HPV16 at elevated risk. Current prevention relies heavily on screening, but unlike cervical cancer, there is no FDA-approved, standardized test for oropharyngeal HPV, making early detection challenging. A topical, user-controlled intervention like the chewing gum could address a critical gap in secondary prevention, particularly for adults who missed vaccination windows or have immunosuppressive conditions.
Oral Global Cancer
Contraindications & When to Consult a Doctor
Individuals with known allergies to cholera toxin or plant-derived proteins should avoid this product until further allergenicity testing is complete. Those with temporomandibular joint (TMJ) disorders, severe bruxism, or recent oral surgery should consult a dentist or oral medicine specialist before regular use, as prolonged chewing may exacerbate jaw discomfort. The gum is not intended to treat active HPV infection, precancerous lesions, or symptomatic cancer—any persistent sore throat, difficulty swallowing, unexplained weight loss, or neck lump lasting more than two weeks warrants prompt medical evaluation, regardless of gum use. It should never replace HPV vaccination, which remains the cornerstone of primary prevention.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
